Wierda, William G. http://orcid.org/0000-0002-7357-270X
Rawstron, Andrew
Cymbalista, Florence
Badoux, Xavier
Rossi, Davide
Brown, Jennifer R. http://orcid.org/0000-0003-2040-4961
Egle, Alexander http://orcid.org/0000-0003-0648-4416
Abello, Virginia http://orcid.org/0000-0001-6507-4041
Cervera Ceballos, Eduardo
Herishanu, Yair
Mulligan, Stephen P.
Niemann, Carsten U. http://orcid.org/0000-0001-9880-5242
Diong, Colin P.
Soysal, Teoman http://orcid.org/0000-0002-7417-2118
Suzuki, Ritsuro http://orcid.org/0000-0002-5974-7614
Tran, Hoa T. T.
Wu, Shang-Ju
Owen, Carolyn
Stilgenbauer, Stephan
Ghia, Paolo http://orcid.org/0000-0003-3750-7342
Hillmen, Peter
Article History
Received: 17 April 2020
Revised: 17 March 2021
Accepted: 23 March 2021
First Online: 24 June 2021
Compliance with ethical standards
:
: WGW received consulting fees from Genzyme and has conducted contracted research for GSK/Novartis, AbbVie, Genentech, Karyopharm, Pharmacyclics, Gilead Sciences, Juno Therapeutics, Kite Pharma, Sunesis, Miragen, Oncternal Therapeutics, Cyclacel, Loxo Oncology, Janssen, and Zencor; AR received grants from AbbVie, Gilead, Janssen, Pharmacyclics, Roche, and Celgene, consulting fees/honoraria from AbbVie, BD Biosciences, Beckman Coulter, Gilead, Janssen, Pharmacyclics, Roche, and Celgene, nonfinancial support from BD Biosciences, Beckman Coulter, and Janssen, and royalties from BD Biosciences; FC received consulting fees from Roche, Janssen, Gilead, AbbVie, AstraZeneca, and Sunesis, grant funding from Sunesis, honoraria for lectures from AbbVie and Janssen, and travel accommodations from Roche, Janssen, Gilead, and AbbVie, XB received funding from AbbVie; DR received honoraria from AbbVie, AstraZeneca, Gilead, Janssen, Roche, and research grants from AbbVie, Gilead, Janssen, Cellestia; JB received consulting fees from AbbVie, Acerta, Beigene, Genentech/Roche, Gilead, Juno/Celgene, Kite, Loxo, Novartis, Pfizer, Pharmacyclics, Sunesis, TG Therapeutics, Verastem, AstraZeneca, Octapharma, Catapult Therapeutics, and Dynamo Therapeutics, honoraria from Janssen and Teva, research funding from Gilead, Loxo Oncology, Verastem, and Sun, and served on the Data Safety Monitoring Board for Morphosys and Invectys; AE received consulting fees and nonfinancial support from AbbVie, Janssen, and Roche; VA received advisory board honoraria, research funding, and travel grants from AbbVie and advisory board honoraria from Janssen; YH has received consulting fees from Janssen and AbbVie; SPM has participated in advisory boards for AbbVie and Janssen, and has been an invited lecturer for Janssen; CN has received grants from AbbVie, Janssen, Roche, and AstraZeneca/Acerta, consulting fees from AbbVie, Janssen, AstraZeneca/Acerta, Sunesis, and CSL Behring; TS received consulting fees and travel grants from AbbVie; RS received consulting fees/honoraria from AbbVie, BMS, Kyowa-Hakko Kirin, Chugai Pharmaceuticals, Shionogi, Takeda, Meiji Seika Pharma, MSD, Ohtsuka, Sawai, Celgene, Sumitomo Dainippon, Eisai, Alexion, Sanofi, Gilead, Mundi, Jazz, Ono, and Janssen; HTTT received consulting fees from AbbVie; SJW received grants from Roche and AbbVie; CO received consulting fees/honoraria from AbbVie, AstraZeneca, Janssen, Merck, Roche, Teva, and Gilead, SS received fees for consulting, drug/equipment, funding, and writing assistance from AbbVie, AstraZeneca, Celgene, Gilead, GlaxoSmithKline, Hoffman La-Roche, Janssen, Novartis, Pharmacyclics, and Sunesis; PG has participated in advisory boards for AbbVie, Acerta/AstraZeneca, Arqule, Dynamo, Gilead, Janssen, Juno/Celgene, and Sunesis, has been an invited lecturer for AbbVie, Janssen, and Gilead, and has received research grants from AbbVie, Gilead, Janssen, Novartis, and Sunesis; PH received grants from AbbVie, Janssen, Pharmacyclics, Roche, and Gilead, and speaking fees from AbbVie and Janssen; EC and CPD have nothing to disclose. AbbVie supported participant attendance at the consensus meetings and provided financial support for third-party medical writing but otherwise had no role in the development of consensus guidelines. AbbVie also participated in the review of the manuscript. No honoraria or payments were made for authorship.